Black Diamond Therapeutics, Inc (BDTX)

Black Diamond Therapeutics, Inc's Q·Score is 6/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.2× debt-to-equity). Key area to monitor: low return on equity (-35%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for BDTX is $9.86, based on ratings from 7 Wall Street analysts. This is 468.1% above the current price of $1.74. Price targets are forward-looking estimates and not guarantees of future performance.

Black Diamond Therapeutics, Inc (BDTX) scores in line with sector averages on valuation metrics. The consensus analyst price target of $9.86 is 468% above the current price.

Black Diamond Therapeutics, Inc's next earnings report is expected on approximately August 6, 2026.

Black Diamond Therapeutics, Inc has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.

Black Diamond Therapeutics, Inc has a debt-to-equity ratio of 0.17×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 8.46×, indicating comfortable short-term liquidity.